{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:42:54Z","timestamp":1780612974786,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06873-w","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:27:32Z","timestamp":1771662452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-0549","authenticated-orcid":false,"given":"Venediktos","family":"Kapetanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-4104","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"Dobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-2621","authenticated-orcid":false,"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-5412","authenticated-orcid":false,"given":"Elena Maria","family":"Elli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4453-6985","authenticated-orcid":false,"given":"Erika","family":"Morsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4926-2727","authenticated-orcid":false,"given":"Filippo","family":"Branzanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7635-7846","authenticated-orcid":false,"given":"Catherine E.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-0028","authenticated-orcid":false,"given":"Nicholas","family":"Ballew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-0231","authenticated-orcid":false,"given":"Kelesitse","family":"Phiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6123-1622","authenticated-orcid":false,"given":"Fulya","family":"Sen Nikitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8523-0419","authenticated-orcid":false,"given":"Shiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwaipayan","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"2","key":"6873_CR1","first-page":"121","volume":"16","author":"JM O\u2019Sullivan","year":"2018","unstructured":"O\u2019Sullivan JM, Harrison CN (2018) Myelofibrosis: clinicopathologic features, prognosis, and management. Clin Adv Hematol Oncol 16(2):121\u2013131","journal-title":"Clin Adv Hematol Oncol"},{"issue":"17","key":"6873_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1056\/nejm200004273421706","volume":"342","author":"A Tefferi","year":"2000","unstructured":"Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342(17):1255\u20131265. https:\/\/doi.org\/10.1056\/nejm200004273421706","journal-title":"N Engl J Med"},{"issue":"5","key":"6873_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A (2023) Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(5):801\u2013821. https:\/\/doi.org\/10.1002\/ajh.26857","journal-title":"Am J Hematol"},{"key":"6873_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/ijgm.S51800","volume":"7","author":"TI Mughal","year":"2014","unstructured":"Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S (2014) Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 7:89\u2013101. https:\/\/doi.org\/10.2147\/ijgm.S51800","journal-title":"Int J Gen Med"},{"issue":"6","key":"6873_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11899-024-00744-9","volume":"19","author":"K Thaw","year":"2024","unstructured":"Thaw K, Harrison CN, Sriskandarajah P (2024) JAK inhibitors for myelofibrosis: strengths and limitations. Curr Hematol Malig Rep 19(6):264\u2013275. https:\/\/doi.org\/10.1007\/s11899-024-00744-9","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"6873_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr., Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"6873_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103862","volume":"180","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Harrison CN, Mesa RA, Kiladjian JJ, Vannucchi AM, Verstovsek S (2022) Anemia in myelofibrosis: current and emerging treatment options. Crit Rev Oncol Hematol 180:103862. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103862","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"6873_CR8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/10428194.2023.2196593","volume":"64","author":"N Pemmaraju","year":"2023","unstructured":"Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S (2023) Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma 64(6):1063\u20131081. https:\/\/doi.org\/10.1080\/10428194.2023.2196593","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"6873_CR9","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30(8):1701\u20131707. https:\/\/doi.org\/10.1038\/leu.2016.148","journal-title":"Leukemia"},{"issue":"suppl 1","key":"6873_CR10","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1182\/blood-2023-179417","volume":"142","author":"V Gupta","year":"2023","unstructured":"Gupta V, Guglielmelli P, Hamer-Maansson J, Braunstein EM, Al-Ali HK (2023) Effect of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib in the expanded-access jump study. Blood 142(suppl 1):5174\u20135174. https:\/\/doi.org\/10.1182\/blood-2023-179417","journal-title":"Blood"},{"issue":"6","key":"6873_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","volume":"6","author":"M Maffioli","year":"2022","unstructured":"Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D\u2019Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji R, Cattaneo D, Della Porta MG, Giorgino T, Bert\u00f9 L, Brociner M, Kuykendall A, Passamonti F (2022) A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv 6(6):1855\u20131864. https:\/\/doi.org\/10.1182\/bloodadvances.2021006889","journal-title":"Blood Adv"},{"issue":"6","key":"6873_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/ejh.13330","volume":"103","author":"F Schain","year":"2019","unstructured":"Schain F, Vago E, Song C, He J, Liwing J, L\u00f6fgren C, Bj\u00f6rkholm M (2019) Survival outcomes in myelofibrosis patients treated with ruxolitinib: a population-based cohort study in Sweden and Norway. Eur J Haematol 103(6):614\u2013619. https:\/\/doi.org\/10.1111\/ejh.13330","journal-title":"Eur J Haematol"},{"issue":"6","key":"6873_CR13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cncr.32664","volume":"126","author":"F Palandri","year":"2020","unstructured":"Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Fo\u00e0 R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N (2020) Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 126(6):1243\u20131252. https:\/\/doi.org\/10.1002\/cncr.32664","journal-title":"Cancer"},{"key":"6873_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107719","volume":"154","author":"F Palandri","year":"2025","unstructured":"Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, Beggiato E, Farina M, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Isidori A, Dedola A, Scalzulli E, Moioli A, Cavalca F, Caserta S, Duminuco A, Martino B, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Bonifacio M, Palumbo GA, Branzanti F, Iurlo A, Abruzzese E (2025) Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: the Italian RUX-MF multicenter study. Leuk Res 154:107719. https:\/\/doi.org\/10.1016\/j.leukres.2025.107719","journal-title":"Leuk Res"},{"key":"6873_CR15","unstructured":"GSK (2023) Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia. GSK. https:\/\/us.gsk.com\/en-us\/media\/press-releases\/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anemia\/. Accessed 04 Sept 2025"},{"key":"6873_CR16","unstructured":"GSK (2024) European Commission authorises GSK\u2019s Omjjara (momelotinib). GSK. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/european-commission-authorises-gsk-s-omjjara-momelotinib\/. Accessed 04 Sept 2025"},{"key":"6873_CR17","unstructured":"GSK (2024) GSK\u2019s Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis. GSK. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis\/. Accessed 04 Sept 2025"},{"issue":"34","key":"6873_CR18","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/jco.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J (2017) SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 35(34):3844\u20133850. https:\/\/doi.org\/10.1200\/jco.2017.73.4418","journal-title":"J Clin Oncol"},{"issue":"2","key":"6873_CR19","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/s2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 5(2):e73\u2013e81. https:\/\/doi.org\/10.1016\/s2352-3026(17)30237-5","journal-title":"Lancet Haematol"},{"issue":"10373","key":"6873_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/s0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 401(10373):269\u2013280. https:\/\/doi.org\/10.1016\/s0140-6736(22)02036-0","journal-title":"Lancet"},{"issue":"45","key":"6873_CR21","doi-asserted-by":"publisher","first-page":"79073","DOI":"10.18632\/oncotarget.18674","volume":"8","author":"F Palandri","year":"2017","unstructured":"Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D\u2019Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M (2017) Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget 8(45):79073\u201379086. https:\/\/doi.org\/10.18632\/oncotarget.18674","journal-title":"Oncotarget"},{"issue":"24","key":"6873_CR22","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1002\/cncr.35489","volume":"130","author":"F Palandri","year":"2024","unstructured":"Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M (2024) Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: the RUX-MF Real-World study. Cancer 130(24):4257\u20134266. https:\/\/doi.org\/10.1002\/cncr.35489","journal-title":"Cancer"},{"issue":"3","key":"6873_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivar Behav Res"},{"key":"6873_CR24","unstructured":"Al-Ali HK, Guglielmelli P, Hamer-Maansson JE, Braunstein E, Gupta V The impact of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib: results from the expanded-access JUMP study. Poster presented at EHA 2024; June 13\u201316, 2024; Madrid, Spain. Poster P1044."},{"key":"6873_CR25","unstructured":"Ojjaara (2025) Highlights of prescribing information. GSK. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Ojjaara\/pdf\/OJJAARA-PI-PIL.PDF. Accessed 18 Aug 2025"},{"key":"6873_CR26","doi-asserted-by":"crossref","unstructured":"Kuykendall AT, Palandri F, Zhang S, Liu T, Fillbrunn M, Zhang A, Sajeev G, Signorovitch J, Patnaik D, Gerds AT Retrospective real-world analysis of survival outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib in the united states. Poster presented at the 66th ASH Annual Meeting & Exposition; December 7\u201310, 2024; San Diego, CA. Poster 3804","DOI":"10.1182\/blood-2024-205380"},{"issue":"11","key":"6873_CR27","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1002\/cncr.34722","volume":"129","author":"F Palandri","year":"2023","unstructured":"Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, Tieghi A, Heidel FH, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Biondo M, Venturi M, Scaffidi L, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Bartoletti D, Paglia S, Vianelli N, Cavo M, Bonifacio M, Palumbo GA (2023) Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome. Cancer 129(11):1704\u20131713. https:\/\/doi.org\/10.1002\/cncr.34722","journal-title":"Cancer"},{"issue":"8","key":"6873_CR28","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/cncr.35156","volume":"130","author":"F Palandri","year":"2024","unstructured":"Palandri F, Palumbo GA, Benevolo G, Iurlo A, Elli EM, Abruzzese E, Polverelli N, Tiribelli M, Auteri G, Tieghi A, Caocci G, Binotto G, Cavazzini F, Branzanti F, Beggiato E, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Scaffidi L, Venturi M, Duminuco A, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Trawinska MM, Vianelli N, Cavo M, Bonifacio M, Breccia M (2024) Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer 130(8):1270\u20131280. https:\/\/doi.org\/10.1002\/cncr.35156","journal-title":"Cancer"},{"issue":"2","key":"6873_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3324\/haematol.2023.283106","volume":"109","author":"R Mesa","year":"2024","unstructured":"Mesa R, Verstovsek S, Platzbecker U, Gupta V, Lavie D, Giraldo P, Recher C, Kiladjian JJ, Oh ST, Gerds AT, Devos T, Passamonti F, Vannucchi AM, Egyed M, Lech-Maranda E, Pluta A, Nilsson L, Shimoda K, McLornan D, Kawashima J, Klencke B, Huang M, Strouse B, Harrison C (2024) Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib. Haematologica 109(2):676\u2013681. https:\/\/doi.org\/10.3324\/haematol.2023.283106","journal-title":"Haematologica"},{"issue":"17","key":"6873_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70062","volume":"131","author":"F Palandri","year":"2025","unstructured":"Palandri F, Branzanti F, Bonifacio M, Elli EM, Morsia E, Farina M, Tiribelli M, Benevolo G, Beggiato E, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Dedola A, Scalzulli E, Duminuco A, Tosoni L, Strazimiri A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Sartor C, Heidel FH, Breccia M, Palumbo GA, Kuykendall AT (2025) Revised \"iRR6\" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib. Cancer 131(17):e70062. https:\/\/doi.org\/10.1002\/cncr.70062","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06873-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06873-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06873-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:51Z","timestamp":1776405591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06873-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6873"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06873-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with all applicable laws regarding patient privacy. No direct subject contact or primary collection of individual human subject data occurred. All study results are presented as aggregate analyses that omit patient identification; therefore, informed consent and ethics committee or IRB approval were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Venediktos Kapetanakis and Bal\u00e1zs Dobi report employment with Evidera, a business unit of Thermo Fisher Scientific, which was contracted to conduct this study by GSK. Massimo Breccia reports honoraria from Novartis, Incyte, GSK, AOP Orphan, AbbVie, Bristol Myers Squibb, Pfizer, Servier, and Otsuka. Catherine Ellis, Nicholas Ballew, Tom Liu, Kelesitse Phiri, Fulya Sen Nikitas, Shiyuan Zhang, and Dwaipayan Patnaik report employment with and stock\/stock options in GSK. Giuseppe A. Palumbo reports honoraria for advisory boards and speakers bureau from AbbVie, AOP Orphan, AstraZeneca, BeiGene, Bristol Myers Squibb, GSK, Incyte, MorphoSys, and Novartis and financial support for travel from AbbVie, AOP Orphan, BeiGene, Bristol Myers Squibb, Johnson & Johnson, Novartis, and Stemline Menarini. Elisabetta Abruzzese reports consultancies and advisory boards from Ascentage, Bristol Myers Squibb, GSK, Incyte, Novartis, and Pfizer. Massimiliano Bonifacio reports honoraria from Amgen, Ascentage, Blueprint Medicines, Bristol Myers Squibb, GSK, Incyte, Novartis, and Pfizer. All authors acknowledge medical writing support for this manuscript, which was funded by GSK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}},{"value":"Venediktos Kapetanakis and Bal\u00e1zs Dobi report employment with Evidera, a business unit of Thermo Fisher Scientific, which was contracted to conduct this study by GSK. Massimo Breccia reports honoraria from Novartis, Incyte, GSK, AOP Orphan, AbbVie, Bristol Myers Squibb, Pfizer, Servier, and Otsuka. Catherine Ellis, Nicholas Ballew, Tom Liu, Kelesitse Phiri, Fulya Sen Nikitas, Shiyuan Zhang, and Dwaipayan Patnaik report employment with and stock\/stock options in GSK. Giuseppe A. Palumbo reports honoraria for advisory boards and speakers bureau from AbbVie, AOP Orphan, AstraZeneca, BeiGene, Bristol Myers Squibb, GSK, Incyte, MorphoSys, and Novartis and financial support for travel from AbbVie, AOP Orphan, BeiGene, Bristol Myers Squibb, Johnson & Johnson, Novartis, and Stemline Menarini. Elisabetta Abruzzese reports consultancies and advisory boards from Ascentage, Bristol Myers Squibb, GSK, Incyte, Novartis, and Pfizer. Massimiliano Bonifacio reports honoraria from Amgen, Ascentage, Blueprint Medicines, Bristol Myers Squibb, GSK, Incyte, Novartis, and Pfizer. All authors acknowledge medical writing support for this manuscript, which was funded by GSK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}